2023-12-14 09:29:27 ET
Moderna Inc (NASDAQ: MRNA) is up nearly 15% this morning after reporting mid-stage trial data for its experimental vaccine for skin cancer.
Moderna vaccine with Keytruda is effective for Melanoma
On Thursday, the pharmaceutical giant said its candidate vaccine in combination with Keytruda (Merck’s blockbuster therapy) reduces the risk of relapse or death in melanoma patients by 49%.
The mixture also lowered the risk of cancer spreading to other body parts by 62%. Stephane Bancel – the Chief Executive of Moderna Inc said in a press release today:
We will begin additional studies in melanoma and other forms of cancer with the goal of bringing truly individualized cancer treatments to patients.
The said outcome was statistically significant than the one observed in patients on Keytruda alone. Moderna stock is still down over 50% versus its year-to-date high in January.
Watch here: https://www.youtube.com/embed/8oVRYQe2bX8?feature=oembedCombination treatment is being tested for other tumour types
Side effects of the aforementioned vaccine after three years include chills, injection site pain, and fatigue, as per the mid-stage trial data posted on Thursday.
The American Cancer Society estimates about 100,000 diagnosis of melanoma in the United States this year. Close to 8,000 of these patients, it expects, will eventually die of skin cancer.
80 yrs ago, people didn't talk about skin cancer.
— Tan Man (@reallytanman) March 31, 2022
Since then, rates have gone up 2000%, and prevalence in children has increased too. https://t.co/3x4LqDuFfZ pic.twitter.com/1TB8zSMMRn
Note that Moderna and Merck & Co Inc (NYSE: MRK) have already initiated a late-stage trial to study the treatment in Melanoma patients. They are testing the combination against other types of tumours as well.
Shares of Merck & Co Inc are marginally down in the premarket on Thursday.
The post Moderna stock popped 15% on Thursday: explore why appeared first on Invezz